JOHNSON & JOHNSON is 178.2x more valuable than Viking Therapeutics, Inc. by market capitalization ($574.10 B vs $3.22 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | VKTX | JNJ |
|---|---|---|
| Market cap | $3.22 B | $574.10 B |
| US-listed rank | #1747 | #20 |
| Revenue (latest FY) | $0.00 | $94.19B |
| Net income (latest FY) | -$359.64M | $26.80B |
| Net margin | - | 28.5% |
| P/E (trailing FY) | - | 21.4 |
| SEC filings | 627 | 984 |
JOHNSON & JOHNSON is 178.2x more valuable than Viking Therapeutics, Inc. by market capitalization ($574.10 B vs $3.22 B).
In their latest fiscal years, Viking Therapeutics, Inc. reported $0.00 in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Viking Therapeutics, Inc. and JOHNSON & JOHNSON, or browse the full rankings.